Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphaël Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John Barnard, Nikolai A. Podoltsev, Andrew Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Gail J. Roboz, Pierre Fenaux, Mark Litzow, Amir T. Fathi, Sarah Perreault, Tae Kon KimThomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)246-249
Number of pages4
JournalLeukemia and Lymphoma
Volume60
Issue number1
DOIs
StatePublished - Jan 2 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Stahl, M., DeVeaux, M., Montesinos, P., Itzykson, R., Ritchie, E. K., Sekeres, M. A., Barnard, J., Podoltsev, N. A., Brunner, A., Komrokji, R. S., Bhatt, V. R., Al-Kali, A., Cluzeau, T., Santini, V., Roboz, G. J., Fenaux, P., Litzow, M., Fathi, A. T., Perreault, S., ... Zeidan, A. M. (2019). Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 60(1), 246-249. https://doi.org/10.1080/10428194.2018.1468893